A combined aqueous extract of Psidium guajava L. and Tithonia diversifolia (Hemsl.) A. gray improves metabolic homeostasis and preserves intestinal integrity in experimental rabbit colibacillosis Authors: Mireille Tuedom Chouegouong, Rufin Marie Toghueo Kouipou, Yanick Kevin Melogmo Dongmo, Jaurès Marius Tsakem Nangap, Michele Stella Majoumouo, Brice Pinlap, Kingsley Agbor Etchu, Fabrice Fekam Boyom, Seth Domfeh, Seth Domfeh, Seth Domfeh, Seth Domfeh Published: 2026 ABSTRACT BackgroundColibacillosis, caused by pathogenic Escherichia coli, remains a significant threat to rabbit production, particularly during the critical weaning period. With the emergence of multidrug-resistant strains limiting conventional antibiotic efficacy, there is an urgent need for sustainable phytotherapeutic alternatives. This study evaluated the therapeutic efficacy of a combined aqueous leaf extract of Psidium guajava L. and Tithonia diversifolia (Hemsl.) A. Gray on systemic biological markers and organ integrity in a rabbit model of colibacillosis.MethodsThirty healthy rabbits were randomly grouped into six cohorts: negative control (infected-untreated), healthy control (uninfected-untreated), positive control (infected-treated with Neomycin 10 mg/kg), immunodepressed (uninfected-cyclophosphamide), and two treatment groups (infected; receiving 400 or 800 mg/kg of the combined P. guajava and T. diversifolia extract). Colibacillosis was induced via oral administration of a pathogenic E. coli isolate (1 mL/100 g body weight; 10⁹ CFU/mL). Systemic recovery was assessed through hematological, biochemical, and antioxidant profiling, alongside histological examination and multivariate Principal Component Analysis (PCA). The data were analysed using OriginLab Pro 2025 and GraphPad Prism version 8.0.1 and all multivariate analyses and visualizations were performed in the R statistical environment (v4.4.3).ResultsE. coli infection triggered severe haematological, biochemical, and inflammatory dysregulation, characterized by significant increases in white blood cell counts, aspartate aminotransferase, creatinine, and triglycerides, concomitant with reduced red blood cell counts, haemoglobin, and albumin. The combined extract demonstrated dose-dependent efficacy. Notably, multivariate PCA mapping revealed that the 800 mg/kg dose achieved a superior therapeutic outcome, effectively resolving clinical diarrhoea and restoring biological profiles to states comparable to those of the healthy and Neomycin-treated cohorts. Furthermore, the extract significantly mitigated systemic oxidative stress and protected organ integrity.ConclusionThese findings demonstrate the therapeutic efficacy and potential of the combined P. guajava and T. diversifolia extract in managing colibacillosis and associated systemic inflammation in rabbits. This study supports the traditional ethnomedicinal use of these plants and demonstrate that these combined extracts could be develop as natural alternatives to synthetic antibiotics in veterinary medicine for managing colibacillosis in rabbits. Introduction In the face of escalating global climate change and the urgent need for sustainable food systems, rabbit farming (Oryctolagus cuniculus) has emerged as an environmentally superior alternative to traditional livestock [1,2]. Characterized by a low carbon footprint, minimal water requirements, and the ability to thrive on non-competitive forage, the domestic rabbit industry is increasingly recognized as a cornerstone of eco-friendly agriculture and a vital contributor to rural economic development and food security worldwide [2]. Global rabbit meat production reached approximately 860,000 tons in 2021, with China leading the sector (53.1%), followed by a growing importance in developing nations [3]. This prominence of farming is driven by the rabbit’s favourable biological characteristics, notably their high fecundity and efficient feed conversion [4]. Furthermore, rabbit meat is a highly nutritious, lean protein source, rich in essential micronutrients such as iron, zinc, and vitamin B12 [5]. Despite this potential, the rabbit farming industry faces substantial health challenges, with enteric diseases representing the most economically devastating hurdle [6]. Infectious diarrhoea remains a primary cause of mortality and reduced growth performance, leading to high veterinary costs [7]. Colibacillosis, caused by enteropathogenic Escherichia coli (EPEC), is the most prevalent bacterial threat to young rabbits [6]. The pathogenesis of EPEC is defined by a sophisticated cytokine cascade: bacterial attachment (BFP) and effector protein injection (T3SS) trigger an immediate innate response (interleukin-1β (IL-1β) and interleukin-6 (IL-6)), which subsequently activates a Th1-mediated adaptive immune response [8]. The resulting attaching and effacing (A/E) lesions destroy the intestinal brush border, compromising the epithelial barrier and allowing systemic cytokines to exacerbate fluid loss and diarrhoea [8]. Furthermore, this bacterial colonization triggers an intense oxidative stress response. The host’s ability to survive this oxidative storm depends heavily on the mobilization of its antioxidant defences system, particularly superoxide dismutase (SOD) and glutathione peroxidase (GPX) [9]. The conventional management of colibacillosis has historically relied on a narrow spectrum of antimicrobials, predominantly trimethoprim-sulfamethoxazole and fluoroquinolones [10]. However, the livestock sector is now at a critical juncture due to the global escalation of antimicrobial resistance (AMR). Recent surveillance indicates a dramatic rise in multidrug-resistant (MDR) E. coli strains in rabbitries, with some isolates exhibiting total resistance to watch-list antibiotics like tetracyclines and aminoglycosides [11,12]. This phenomenon is not merely a veterinary concern, but a significant public health threat, as the transmission of resistant genes from livestock to the human food chain complicates the treatment of enteric infections in people [13,14]. Furthermore, the increasing regulatory restrictions on antibiotic growth promoters (AGPs) and the growing consumer demand for antibiotic-free animal products have rendered the status quo untenable [15,16]. Consequently, there is an urgent imperative to transition toward sustainable, bio-based therapeutic alternatives that can achieve clinical resolution without contributing to the environmental resistome. Ethnoveterinary medicine offers a robust reservoir for therapeutic discovery, particularly through species such as P. guajava. (Myrtaceae) and T diversifolia (Asteraceae). While P. guajava is widely used for its tannin-rich antidiarrheal properties [17] and T. diversifolia for its anti-inflammatory sesquiterpene lactones [18], their selection for this study was based on the results from our previous investigation. In our preceding ethnopharmacological survey of rabbitries in Cameroon, these two species emerged as the most prominent remedies used by local farmers to manage bacterial enteritis [19]. Subsequent in vitro screening of forty-five different preparations revealed that only six extracts, exhibited potent antibacterial activity against pathogenic E. coli. Notably, the combination of T. diversifolia and P. guajava yielded a synergistic interaction, achieving a Fractional Inhibitory Concentration Index (FICI) as low as 0.265 and reducing individual minimum inhibitory concentration (MIC) values by up to 64-fold [19]. This specific formulation demonstrated a high biological potency index, consistently maintaining activity levels that justify further investigation. Consequently, the present study was designed to validate these synergistic findings in vivo, utilizing an integrated multivariate approach to determine if the combination of P. guajava and T. diversifolia extracts can resolve systemic colibacillosis and restore host homeostasis as effectively as conventional antibiotherapy. Materials and methods Ethical approval, ethical statement, and animal welfare All experimental protocols were reviewed and approved by the Cameroon National Ethical Committee (Ref No. FWIRB00001954). The study was conducted in strict accordance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments). Ethnobotanical selection and extract preparation The selection of plant materials was based on our previous ethnopharmacological survey, identifying active remedies against rabbit bacterial enteritis [19]. Fresh leaves of P. guajava (Myrtaceae) and T. diversifolia (Hemsl.) A. Gray (Asteraceae) were collected in April 2024 (corresponding to the onset of the rainy season) at approximately 07:00 h (local time) in Yaoundé, Cameroon. The botanical samples were authenticated at the National Herbarium of Cameroon (Voucher Nos. 2884 SRFK and 57410 HNC, respectively). The fresh leaves were air-dried at ambient temperature (25°C) for 14 days until a constant weight was achieved, followed by mechanical pulverization into a fine powder. Fresh leaves of Psidium guajava weighing 2,204 g produced 500 g of dry powder, corresponding to an approximate fresh-to-dry ratio of 4.4:1. Similarly, 3,774 g of fresh Tithonia diversifolia leaves yielded 500 g of dry powder, equivalent to an approximate fresh-to-dry ratio of 7.5:1. The extracts were prepared using cold extraction with distilled water at room temperature to mimic the traditional preparation, ensuring high extraction yield. 500 g of powder from each plant species was macerated in 2 L of distilled water for 72 h under continuous agitation. The mixtures were filtered through hydrophilic cotton, and the filtrates were dehydrated under forced ventilation at 25°C to remove the residual solvent. The resulting crude extracts were stored at −20°C. Preparation of the combined extract solutions Combined extract formulations of P. guajava and T. diversifolia were freshly prepared in distilled water daily. The ratio of the two extracts within the combination (96.975% P. guajava and 3.025% T. diversifolia) was determined based on the synergistic Fractional Inhibitory Concentration Index (FICI = 0.265) identified in our prior in vitro assays [19]. Two distinct stock solutions were prepared to deliver target doses of 400 and 800 mg/kg body weight using a standardized oral gavage volume of 1 mL per 100 g body weight, equivalent to 10 mL/kg body weight. The stock solution of 40 mg/mL (for the 400 mg/kg group) was prepared by dissolving 310.32 mg of P. guajava extract and 9.68 mg of T. diversifolia extract in 8 mL of sterile distilled water. This delivered 387.9 mg/kg of P. guajava and 12.1 mg/kg of T. diversifolia in vivo. The second stock solution of 80 mg/mL (for the 800 mg/kg group) was prepared by dissolving 620.64 mg of P. guajava extract and 19.36 mg of T. diversifolia extract in 8 mL of sterile distilled water. This delivered 775.8 mg/kg of P. guajava and 24.2 mg/kg of T. diversifolia in vivo. Characterization and virulence of the clinical isolate A clinical isolate of E. coli was recovered from a rabbit presenting acute colibacillosis symptoms. Identification was performed using the API 20E analytical profile index (bioMérieux, France). Virulence potential was assessed via the Congo red binding assay [20] on tryptic soy agar supplemented with 0.003% Congo red and 1.5% bile salts. Red-pigmented colonies, indicative of virulent plasmid expression, were selected and cultured in nutrient broth supplemented with bile salts (0.4%). Inoculum turbidity from a 24-hour culture was adjusted to 4 McFarland, corresponding to a concentration of approximately 109 CFU/mL in sterile 0.9% saline [21]. Experimental animals Thirty hybrid rabbits (mixed sex: three females and two males, 6–7 weeks old, 800–900 g) were acclimatized for 7 days at the Laboratory of Phytobiochemistry and Medicinal Plant Studies, University of Yaoundé I. Animals were housed in pairs in galvanized cages (35 cm × 40 cm × 60 cm) under a 12-hour light/dark cycle. They were provided ad libitum access to water and a standard pelleted diet (composition: 21 kg corn flour, 4 kg cassava flour, 20 kg Pennisetum sp., 31 kg wheat bran, 8 kg palm kernel cake, 6 kg soybean cake, 1 kg bone meal, 4 kg palm oil, and 5 kg dried fish). Following acclimatization, rabbits were weighed to establish a baseline, ensuring comparable mean body weights across all experimental groups. Experimental design and induction of colibacillosis Animals were randomly assigned to one of six experimental cohorts (n = 5 per group) using a computer-generated randomization sequence (www.random.org), to ensure unbiased group allocation. Throughout the study, the investigators adhered to a strict blinding protocol; all samples and histological slides were labelled with anonymous codes, which were unblinded only after the completion of the final statistical analysis. The experimental groups were designated as follows: T0 (normal control, non-infected, receiving sterile water), T1 (negative control, infected, untreated), T2 (positive control, infected, treated with Neomycin 10 mg/kg p.o. for 5 days), T3 (low dose, infected, 400 mg/kg combined extract p.o.), T4 (high dose, infected, 800 mg/kg combined extract p.o.), and T5 (immunosuppression control, non-infected, receiving 30 mg/kg cyclophosphamide i.p.). The rabbits in groups T1 to T4 were pretreated 48 hours before E. coli inoculation with a combination of cyclophosphamide (30 mg/kg body weight, administered intraperitoneally) and streptomycin (150 mg/kg bw, orally) to establish an experimental model of acute colibacillosis. This dual-pretreatment protocol is essential in adult lagomorphs, as streptomycin disrupts resident microflora to overcome colonization resistance, while cyclophosphamide induces a transient state of immunosuppression, effectively mimicking the susceptibility of weanling or immunologically stressed rabbits to enteropathogenic E. coli colonization. Following these physiological disruptions, colibacillosis was induced in groups T1 through T4 via oral gavage of 1 mL of an E. coli suspension (109 CFU/mL in 0.9% saline). Therapeutic interventions were administered daily (10 mL/kg bw) for 7 consecutive days, commencing 24 hours post-infection. To ensure uniform experimental conditions and control for handling stress, animals in the T5 group, pretreated with cyclophosphamide (30 mg/kg bw, intraperitoneally) received a daily oral gavage of the vehicle (10 mL/kg bw of sterile distilled water) for the same 7-day duration. Clinical and microbiological monitoring Daily faecal samples were collected to quantify bacterial shedding. Stool samples (10 mg) were serially diluted (10−5) in sterile saline and plated on MacConkey agar. After 24 h incubation at 37°C, typical E. coli colonies were counted and expressed as Log10 CFU/g of stool. Growth performance was monitored by weighing rabbits every two days. Ethical considerations and humane endpoints A strict clinical monitoring protocol was implemented due to the risk of severe morbidity associated with inducing acute colibacillosis. Rabbits were monitored three times daily (every 8 hours) by for clinical signs of distress. Humane endpoints were strictly defined as: (i) loss of >20% of initial body weight; (ii) severe lethargy or inability to access food/water; (iii) persistent recumbency or lack of righting reflex; (iv) laboured or agonal breathing; and (v) hypothermia or severe dehydration (skin tent >2 seconds). To avoid needless suffering, animals that satisfied one or more of these criteria were immediately subjected to humane euthanasia. In this study, only one animal in the T1 (Negative Control) group reached humane endpoints on Day 3 post-infection due to severe dehydration and was euthanized immediately. No animals died spontaneously during the experimental period. Anaesthesia and methods of sacrifice On Day 7 post-infection (PI), a total of 24 surviving rabbits (n = 4 per group) were humanely sacrificed for sample collection. The remaining five healthy animals from the treatment groups were excluded from terminal sampling and were maintained under standard husbandry conditions for continued post-experimental monitoring. Rabbits were transferred to a separate, quiet procedure room to promote animal welfare and preserve the integrity of the experimental data. Animals were fasted for 12 hours before euthanasia to reduce anaesthesia-related complications. Deep surgical anaesthesia was induced via intramuscular injection of ketamine (30 mg/kg) combined with diazepam (10 mg/kg). The depth of anaesthesia was strictly verified by the complete abolition of the pedal withdrawal and corneal reflexes before any procedures commenced. Euthanasia was completed under deep anaesthesia via cervical dislocation (for rabbits under 1 kg) or exsanguination via cardiac puncture, ensuring a rapid and painless death in accordance with AVMA Guidelines for the Euthanasia of Animals. Sample collection, systemic antioxidant and histopathological analysis Blood was collected for haematology (EDTA tubes) and serum biochemistry (dry tubes). Haematological parameters included white blood cells (WBC), red blood cells (RBC), Haemoglobin (HGB), Haematocrit (HCT), and leukocyte differentials, analysed using a Mindray BC-5300 automated analyser. Serum biochemistry included Alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma-Glutamyl Transferase (GGT), Creatinine, Uric Acid, Total Protein, and lipid profile, including Total Cholesterol (TC), Triglycerides (TG), and High-Density Lipoprotein cholesterol (HDL), analysed using commercial kits (LABKIT, France). Cytokine levels [Tumor Necrosis Factor alpha (TNF-α), interleukin-1beta (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), and C-reactive protein (CRP)] were quantified via sandwich ELISA (Quantikine® Rabbit ELISA kits, Sigma-Aldrich). Tissue samples from the ileum and caecum, liver, and kidney were collected post-mortem for antioxidant assays and histopathological analysis. Ileum and caecum segments were homogenized in 50 mM Tris-HCl buffer (pH 7.4) and centrifuged at 1500 g for 25 min. Supernatants were analysed for Malondialdehyde (MDA) [22], reduced glutathione (GSH) [23], Superoxide dismutase (SOD) [24] and Catalase (CAT) [25]. For histopathological evaluation, liver, kidney, and caecum sections were fixed in 10% buffered formalin, embedded in paraffin wax. Sections (5 μm thick) were cut using a rotary microtome and stained with haematoxylin and eosin (H&E). Photomicrographs were captured using a digital camera attached to a light microscope. Tissue sections were subjected to a rigorous, independent qualitative descriptive analysis focusing on the presence, distribution, and resolution of classical pathological signs associated with enteric E. coli infection, including epithelial desquamation, villous blunting, inflammatory cell infiltration, and vascular congestion. After all sample collection, rabbit carcasses were autoclaved before disposal in compliance with biosafety regulations. Advanced statistical and multivariate analysis The data were analysed using OriginLab Pro 2025 and GraphPad Prism version 8.0.1 (GraphPad Software, San Diego, CA, USA). All quantitative data are expressed as mean ±standard deviation (SD). Before hypothesis testing, the normality of data distribution was verified using the Shapiro–Wilk test, and homogeneity of variances was confirmed via Levene’s test. Univariate comparisons across the six experimental groups were performed using one-way Analysis of Variance (ANOVA), followed by Tukey’s Honest Significant Difference (HSD) post-hoc test to control for multiple comparison inflation and Type I error accumulation. Statistical significance was defined at P < 0.05. An integrated multivariate approach was performed in the R Studio environment (v4.4.3) to evaluate the holistic therapeutic trajectory. Principal Component Analysis (PCA) was utilized to reduce dataset dimensionality, with variables auto-scaled (mean-centred and standardized) to account for differing units. We further generated a global biological fingerprint using hierarchical clustering, where heatmaps were constructed from Z-score-normalized data using Euclidean distance and Ward’s linkage method to visualize metabolic and inflammatory shifts across cohorts. A direct comparison between the 800 mg/kg dose and Neomycin (10 mg/kg) was conducted to assess clinical non-inferiority, defined by the absence of significant divergence (P > 0.05) in recovery endpoints. The study sample size (n = 4 per group) was justified by an a priori power analysis. Based on historical indices of acute enteric inflammation (anticipating a Cohen’s f ≥ 0.70), this sample size was sufficient to achieve a statistical power (1 – β) of 0.80 at α = 0.05, consistent with the 3Rs (Reduction) ethical framework. All multivariate analyses and visualizations were performed in the R statistical environment (v4.4.3) using the tidyverse for data manipulation, FactoMineR and factoextra for multivariate modelling, and ggplot2 (ggrepel) for high-resolution, colour-blind friendly graphical representation. Results Biochemical identification of E. coli isolates and virulence testing The clinical isolate recovered from symptomatic rabbits was subjected to standardized biochemical characterization using the API 20E system (bioMérieux, Marcy l’Etoile, France). The isolate exhibited characteristic carbohydrate fermentation patterns, including positive reactions for glucose, sorbitol, and arabinose, while remaining negative for urease and H2S production. The resulting biochemical profile confirmed the identity of the pathogen as E. coli with an identification probability of 100% (API 20E profile 5044572; identification quality: very good; probability: 100% for E. coli 1), validating its use for the subsequent experimental infection model (Fig 1, S1 Table in S1 File). The virulence potential of the E. coli isolate was phenotypically confirmed via the Congo red binding assay. The isolate exhibited strong dye uptake, resulting in distinct, red-pigmented colonies (CR+) after 24 hours of incubation (S1 Fig in S1 File). This positive phenotype indicates the presence of virulence-associated surface proteins and curli fimbriae, validating the isolate’s capacity for host colonization and its suitability for inducing experimental colibacillosis. Phenotypic characterization of the pathogenic E. coli isolate using the API 20E analytical profile index system. Photograph of an API 20E strip (bioMérieux, Marcy-l’Étoile, France) showing the colorimetric reaction pattern generated by the clinical isolate across the 20 miniaturised biochemical test compartments after 24 h of incubation at 37 °C. The resulting 7-digit numerical profile (5044572) identified the isolate as Escherichia coli with an excellent identification percentage (>99.9%), determined using the apiweb identification software (bioMérieux). The isolate was subsequently confirmed as pathogenic using the Congo red binding assay (see Methods) prior to use in the experimental challenge described in Figs 2–14. Effects of the combination of Psidium guava and Tithonia diversifolia extracts on the body weight of experimentally infected rabbits The effect of E. coli infection and subsequent treatment with the combination of T. diversifolia and P. guajava extracts on the growth trajectory of rabbits is presented in Fig 2 (S2 Table in S1 File). Following the experimental challenge, a significant divergence in body weight was observed between the study cohorts. The infected, untreated group (T1) exhibited a sharp and persistent decline in body weight throughout the 7-day post-infection (PI) period. This pathological weight loss is associated with severe malabsorption of nutrient and dehydration from infectious diarrhoea. Effect of the combined aqueous extracts of Psidium guajava and Tithonia diversifolia on the body weight variation in colibacillosis-infected rabbits. Longitudinal relative body weight variation (%, expressed relative to the Day 0 pre-infection baseline) monitored over 8 days following Escherichia coli challenge in six experimental groups: Normal (uninfected, untreated control); Immunosuppressed (uninfected, cyclophosphamide-only control); Untreated (infected, untreated); Neomycin (infected, treated with neomycin, 10 mg/kg body weight (bw), reference antibiotic); 400 mg/kg bw (infected, treated with the combined extract at the low dose); and 800 mg/kg bw (infected, treated with the combined extract at the high dose). Data are mean ± standard deviation (SD), n = 4 animals per group. Group differences at each time point were assessed by two-way repeated-measures ANOVA followed by Tukey’s honestly significant difference (HSD) post-hoc test (GraphPad Prism version 8.0.1; GraphPad Software, San Diego, CA, USA); P < 0.05 was considered significant. In contrast, rabbits treated with the combined P. guajava and T. diversifolia extracts exhibited a reversal of the infection-induced weight loss. From Day 3 post-infection (PI) onward, the 800 mg/kg dose (T4) promoted body weight gain following a trajectory like that of the healthy control (T0) and Neomycin-treated (T2) groups (P < 0.05). However, the 400 mg/kg dose (T3) resulted in moderate weight recovery, indicating a clear dose-dependent therapeutic response. Notably, the 800 mg/kg dose demonstrated efficacy in restoring rabbits to their pre-infection growth curves. These results suggest that the combined extract could be facilitating nutrient assimilation and helping restore osmotic and fluid-solute equilibrium. Effect of the combination of Psidium guava and Tithonia diversifolia extracts on the relative weight of some vital organs The macroscopic effect of E. coli infection and the safety profile of the combined P. guajava and T. diversifolia extracts treatment were evaluated through relative organ weight analysis and visual inspection (Fig 3). Upon necropsy, all treatment groups exhibited normal organ coloration and morphology, with no visible lesions or congestion in the liver, kidneys, or heart. Statistical analysis revealed that the relative weights of the kidneys and liver in both the 400 and 800 mg/kg extract groups showed no significant variation (P > 0.05) when compared to the healthy control (T0) and the Neomycin-treated (T2) groups. Relative organ weights at sacrifice (Day 7 post-infection) in rabbits challenged with Escherichia coli and treated with the combined Psidium guajava and Tithonia diversifolia extracts. Boxplots of relative organ weights (g organ weight per 100 g body weight) for the heart, kidney, liver, lung and spleen, recorded at necropsy on Day 7 post-infection. Boxes show the median and interquartile range (IQR); whiskers extend to the most extreme values within 1.5 × IQR; individual points represent single animals (n = 4 per group). Experimental groups (Normal, Immunosuppressed, Untreated, Neomycin, 400 mg/kg, 800 mg/kg) are as defined in Fig 2. Between-group differences were assessed by one-way ANOVA followed by Tukey’s HSD post-hoc test (GraphPad Prism v8.0.1); P < 0.05 was considered significant. Notably, the 800 mg/kg cohort (T4) maintained liver and spleen weights comparable to healthy controls, contrasting with the inflammatory oedema and reactive splenomegaly typically observed in untreated colibacillosis. In the infected-untreated group (T1), increased relative spleen weight suggested a heightened systemic immune response to the bacterial load. Conversely, treatment with the P. guajava and T. diversifolia combination effectively preserved organ homeostasis. These results suggest that the extract could be providing systemic protection against E. coli-induced pathology while maintaining the structural integrity of vital metabolic organs, without inducing adverse toxic effects. Therapeutic efficacy and in vivo bacterial clearance of the combination of P. guajava and T diversifolia The in vivo antibacterial potency of the P. guajava and T. diversifolia combination was assessed by monitoring the temporal kinetic of E. coli shedding in the faeces (Fig 4, S3 Table in S1 File). Bacterial load is a critical indicator of the extract’s ability to disrupt intestinal colonization and prevent further mucosal invasion. Following the experimental challenge, all infected groups exhibited peak bacterial shedding (109 CFU/10 mg stool) before the initiation of therapy. Fecal Escherichia coli shedding kinetics in rabbits treated with the combined Psidium guajava and Tithonia diversifolia extracts. Longitudinal fecal bacterial load, expressed as colony-forming units (CFU) × 10⁷ per 10 mg of stool, monitored across the study timeline in five experimental groups: Normal, Untreated, Neomycin (10 mg/kg bw), 400 mg/kg bw and 800 mg/kg bw (group definitions as in Fig 2). Timeline phases are indicated above the plot: D, dietary deprivation/acclimatisation period; ID, immunosuppression (cyclophosphamide administration, Day 3); IF, bacterial infection/challenge (Day 5); T, treatment period; S, sacrifice (Day 13). Data are mean ± SD, n = 4 animals per group. Treatment led to a progressive, time-dependent reduction in bacterial shedding across all cohorts. While the reference antibiotic (Neomycin, T2) achieved complete bacterial clearance within 72 hours (Day 3), the combined P. guajava and T. diversifolia extracts also demonstrated potent curative efficacy. Specifically, both the 400 mg/kg (T3) and 800 mg/kg (T4) doses resulted in no quantifiable bacterial load in faeces by Day 5 of treatment. This 5-day clearance window is clinically significant, as it correlates with the rapid resolution of diarrheic symptoms and the reversal of infection-induced weight loss observed (Fig 3). Collectively, these results indicate that the combined extract exhibits effective, dose-dependent curative activity against E. coli, achieving clinical recovery comparable to the reference antibiotic. These findings demonstrate that the P. guajava and T. diversifolia formulation particularly the 800 mg/kg dose could be a promising biological alternative for the management of clinical colibacillosis. The effect of combined aqueous extract treatment on the Antioxidant defense The impact of E. coli infection and subsequent treatment with combined P. guajava and T. diversifolia extracts on the intestinal redox landscape was evaluated (Fig 5; S4 Table in S1 File). In the infected-untreated cohort (T1), experimental colibacillosis induced a state of biochemical collapse within both the caecum and ileum. This pathological state was characterized by a significant increase (P < 0.05) in MDA levels linked to extensive lipid peroxidation, suggesting the depletion of the primary antioxidant defences, including SOD, CAT, and GSH. These findings demonstrated that E. coli colonization rapidly exhausts the host’s local antioxidant protection, leading to oxidative tissue damage. Effect of the combined Psidium guajava and Tithonia diversifolia extracts on intestinal oxidative stress markers on Day 7 post-infection. Boxplots comparing oxidative stress and antioxidant biomarkers in the caecum (left column) and ileum (right column): catalase (CAT) activity, expressed in millimoles of hydrogen peroxide (H2O2) consumed per minute per gram of tissue; reduced glutathione (GSH) concentration, expressed as × 10-6 µmol per gram of tissue; malondialdehyde (MDA) concentration, an indicator of lipid peroxidation, expressed as × 10-6 µmol per gram of tissue; and superoxide dismutase (SOD) activity, expressed in units per gram of tissue. Experimental groups (Normal, Untreated, Neomycin, 400 mg/kg, 800 mg/kg, Immunosuppressed) are as defined in Fig 2; n = 4 animals per group. Boxes show median and IQR; whiskers extend to 1.5 × IQR. Between-group comparisons: one-way ANOVA with Tukey’s HSD post-hoc test (GraphPad Prism v8.0.1); P < 0.05 was considered significant. Therapeutic administration of the P. guajava and T. diversifolia extracts effectively reversed this oxidative trend in a dose-dependent manner. While the 400 mg/kg dose (T3) provided moderate protection, the 800 mg/kg dose (T4) achieved a superior restorative profile, returning MDA, CAT, and SOD levels to values statistically similar from those of the healthy control (T0). Interestingly, in specific parameters such as caecal GSH and ileal SOD, the 800 mg/kg dose of combined P. guajava and T. diversifolia extracts treatment maintained the antioxidant levels that were numerically superior to the Neomycin standard (T2). This could indicate that while Neomycin serves as a potent bactericidal agent, the combined P. guajava and T.diversifolia extracts could be providing a dual-action benefit by simultaneously preventing the E. coli colonization but also restoring the intestinal antioxidant framework. The effect of combined aqueous extract treatment on haematological stabilization and resolution of systemic inflammation The systemic impact of the E. coli challenge and the subsequent restorative effects of the P. guajava and T. diversifolia combination are summarized in the haematological profiles (Fig 6; S5 Table in S1 File). The infected-untreated group (T1) exhibited a classic septic hemogram, characterized by profound leucocytosis and thrombocytosis. Specifically, WBC counts nearly doubled and Platelet (PLT) counts nearly tripled compared to the healthy control (T0), signalling a severe systemic inflammatory response and the activation of the host’s emergency myeloid defences against E. coli septicaemia. Hematological profile of rabbits on Day 7 post-infection following treatment with the combined Psidium guajava and Tithonia diversifolia extracts. Boxplots of hematological parameters: granulocyte percentage (GRA %); hematocrit (HCT, %); hemoglobin concentration (HGB, g/dL); lymphocyte percentage (LYM %); percentage of mid-sized cells (MID %; combined monocyte, eosinophil and basophil fraction); platelet count (PLT, × 10³/µL); red blood cell count (RBC, × 10⁶/µL); and white blood cell count (WBC, × 10³/µL). Six experimental groups as defined in Fig 2; n = 4 animals per group. Boxes show median and IQR; whiskers extend to 1.5 × IQR; individual points represent single animals. Between-group comparisons: one-way ANOVA with Tukey’s HSD post-hoc test (GraphPad Prism v8.0.1); P < 0.05 was considered significant. Simultaneously, the T1 cohort suffered from anaemia of infection, evidenced by significant declines (P < 0.05) in RBC counts, HGB levels, and HCT compared to all other groups. This erythrocytic collapse likely reflects the combined effects of bacterial hemolysins, iron sequestration, and the haemorrhagic nature of the colibacillosis-induced intestinal lesions. Treatment with the combined P. guajava and T. diversifolia extracts achieved near-complete normalization of the hemogram in a dose-dependent manner. The 800 mg/kg dose (T4) proved to be particularly effective, successfully restoring the systemic inflammatory response by returning WBC and PLT counts to baseline levels. Furthermore, the bioactive extract reversed the erythrocytic decline, restoring haemoglobin concentrations from a pathological low of approximately 11 g/dL to a healthy 15 g/dL. Notably, the leukocyte differential (GRA%, LYM%, and MID %) was rebalanced in the T4 group, indicating a restored and functional immune landscape comparable to the neomycin-treated (T2) and healthy (T0) cohorts. These findings underscore the extract’s potent haematoprotective efficacy and its ability to halt the progression of the infection from a local gut disturbance to a systemic crisis. Immunomodulatory effects of combined aqueous extract treatment on E. coli-infected rabbits The immunological response to E. coli infection and the restorative capacity of the combined P. guajava and T. diversifolia extracts intervention were evaluated through key pro-inflammatory and anti-inflammatory biomarkers (Fig 7; S6 Table in S1 File). In the infected-untreated cohort (T1), experimental colibacillosis triggered a massive cytokine production, evidenced by significant elevations (P < 0.05) in CRP, TNF-α, IL-1β, and IL-6. This excessive release of innate first-responder cytokines drives the systemic inflammatory response, leading to tissue damage and metabolic exhaustion observed in the T1 group. Systemic cytokine and acute-phase protein modulation by the combined Psidium guajava and Tithonia diversifolia extracts on Day 7 post-infection. Boxplots of serum concentrations of C-reactive protein (CRP, ng/mL), interferon-gamma (IFN-γ, ng/mL), interleukin-6 (IL-6, pg/mL), interleukin-10 (IL-10, pg/mL), interleukin-1β (IL-1β, pg/mL), interleukin-3 (IL-3, pg/mL) and tumor necrosis factor-alpha (TNF-α, pg/mL). Six experimental groups as defined in Fig 2; n = 4 animals per group, except where individual values fell below the analytical lower limit of detection, in which case the corresponding data point is omitted from the panel. Between-group comparisons: one-way ANOVA with Tukey’s HSD post-hoc test (GraphPad Prism v8.0.1); P < 0.05 was considered significant. Oral administration of the P. guajava and T. diversifolia combination at 400 and 800 mg/kg induced a significant reduction in these pro-inflammatory markers. Notably, for critical indicators like TNF-α and IL-6, the 800 mg/kg dose (T4) was more potent, suppressing cytokine levels as effectively as the Neomycin standard (T2). This suggests that the bioactive metabolites in the extract, such as flavonoids and sesquiterpene lactones, likely modulate the underlying signalling pathways (such as NF-kB) responsible for acute inflammatory cascades. Conversely, the anti-inflammatory cytokine IL-10 showed a distinct and clinically relevant pattern. While IL-10 levels were significantly lower in the untreated group (T1), all treated cohorts (T2, T3, T4) maintained significantly higher concentrations of this cytokine (P < 0.05). This could be an indication that the combined P. guajava and T. diversifolia extract does not merely suppress the immune system; rather, it facilitates immunological rebalancing by promoting an anti-inflammatory environment that accelerates tissue healing and the resolution of diarrhoea. The normalization of CRP, a standard marker of acute systemic inflammation in rabbits, further validates that the T4 dose achieved complete systemic resolution of the infection. Effects of combined aqueous extract treatment on Hepato-Renal Protection and Metabolic Homeostasis in E. coli-infected rabbits The systemic metabolic profile and organ-functional integrity of the experimental rabbits are summarized in Fig 8 (S7 Table in S1 File). Induction of colibacillosis in the untreated cohort (T1) resulted in significant biochemical derangement (P < 0.05), characterized by a dyslipidaemia of infection and acute hepato-renal distress. Specifically, T1 rabbits exhibited an increase in serum transaminases (AST, ALT) and GGT, signalling acute hepatocellular injury and membrane leakage induced by bacterial endotoxins. Hepatic and renal function markers in rabbits treated with the combined Psidium guajava and Tithonia diversifolia extracts on Day 7 post-infection. Boxplots of serum alanine aminotransferase (ALAT, IU/L), aspartate aminotransferase (ASAT, IU/L), creatinine (mg/dL), gamma-glutamyl transferase (GGT, IU/L), total protein (mg/dL) and uric acid (mg/dL) concentrations. Six experimental groups as defined in Fig 2; n = 4 animals per group. Between-group comparisons: one-way ANOVA with Tukey’s HSD post-hoc test (GraphPad Prism v8.0.1); P < 0.05 was considered significant. Renal function was similarly compromised in the untreated group, with Creatinine and Urate levels nearly doubling. This elevation may indicate a reduced Glomerular Filtration Rate (GFR), likely secondary to infection-induced dehydration and septic renal injury. Furthermore, a state of hypoproteinaemia and hypoalbuminemia was observed in T1, reflecting the systemic inflammatory response and potential protein-losing enteropathy associated with severe diarrhoea. Therapeutic intervention with the P. guajava and T. diversifolia extracts effectively shielded the primary metabolic organs from this endotoxicity. The 800 mg/kg dose (T4) achieved a metabolic reset, returning AST, GGT, Creatinine, and Urate to baseline levels that were statistically indistinguishable from those of the healthy controls (T0). Notably, the extract restored the lipid profile by lowering triglycerides and LDL-cholesterol while significantly increasing HDL-cholesterol (P < 0.05) compared to the untreated group. By stabilizing hepatocellular membranes and maintaining renal blood flow, the 800 mg/kg dose showed organ-protective effects. This helped restore systemic balance comparable to the neomycin-treated group (T2). Integrated hierarchical clustering: The global biological fingerprint Hierarchical clustering analysis was performed on the integrated biological dataset to visualizes the holistic therapeutic trajectory of the rabbits (Fig 9). The resulting heatmap successfully discriminated between the various experimental cohorts, establishing a clear molecular signature for both the pathological state and the subsequent recovery. The infected-untreated cohort (T1) formed a distinct cluster characterized by a massive upregulation of pro-inflammatory and damage-associated markers, specifically manifesting as elevated AST, creatinine, MDA, and pro-inflammatory cytokines (TNF-α, IL-6). Two-way hierarchical clustering heatmap of the integrated physiological profile of rabbits at the study endpoint. Row-standardised (Z-score) heatmap of measured parameters (rows) grouped into five physiological categories: relative organ weights, hematological markers, serum biochemical markers, intestinal antioxidant markers, and longitudinal rabbit body weight (Days 7, 9, 11 and 13 post-infection). Columns represent the six experimental groups (800 mg/kg, Neomycin, 400 mg/kg, Normal, Immunosuppressed, Untreated), each summarising n = 4 animals. Red indicates values above the overall parameter mean (Z-score up to +2), blue indicates values below the mean (Z-score down to −2), and white/pale pink indicates values near the mean. Row and column dendrograms represent unsupervised hierarchical clustering based on Euclidean distance with complete linkage. Parameter abbreviations: GRA %, granulocyte percentage; LYM %, lymphocyte percentage; MID %, mid-sized cell percentage; WBC, white blood cells; PLT, platelets; HGB, hemoglobin; RBC, red blood cells; HCT, hematocrit; CHO, total cholesterol; ASAT, aspartate aminotransferase; LDL, low-density lipoprotein; GGT, gamma-glutamyl transferase; ALAT, alanine aminotransferase; TG, triglycerides; HDL, high-density lipoprotein; SOD, superoxide dismutase; GSH, reduced glutathione; MDA, malondialdehyde. In stark contrast, the cohort treated with 800 mg/kg of combined P.guajava and T. diversifolia extracts (T4) exhibited a reversal of this fingerprint. The T4 group clustered closely with the healthy control (T0) and the neomycin-treated (T2) groups, displaying a synchronized restoration of antioxidant enzymes (SOD, CAT, GSH) and a normalization of systemic biochemical indices. This global transition from the oxidative-inflammatory cluster to the homeostatic cluster underscores the multifaceted curative potential of the P. guajava and T. diversifolia combination. These results could be suggesting that the bioactive extract does not merely target isolated symptoms but induces a systemic homeostatic restoration, restoring the animal’s physiological state to its pre-infection baseline. Multivariate trajectory and key biological drivers Principal Component Analysis (PCA) was applied to the combined dataset as an exploratory tool to visualize the overall multidimensional relationships and clustering trends across the experimental cohorts (Fig 10A). The unsupervised PCA model revealed a visible separation among groups, with the first two dimensions capturing a cumulative total of 57.7% of the total variance. Principal Component 1 (Dim1), which accounted for 48.0% of the variance, served as the primary axis of separation, segregating the coordinates of the infected-untreated cohort (T1) from the clustering space of the healthy controls (T0). Notably, the 800 mg/kg cohort (T4) exhibited a spatial shift along Dim1, positioning itself in closer proximity to the multivariate space occupied by the T0 and Neomycin (T2) groups. This spatial alignment suggests an exploratory trend wherein the global physiological profile of the high-dose extract cohort reflects an orientation toward the healthy and reference treatment spaces. However, given the exploratory nature of this analysis and the lack of an independent validation dataset, these spatial configurations represent descriptive clustering behaviours rather than definitive proof of systemic homeostatic equivalence. Multivariate trajectory and key biological drivers of the therapeutic response. (A) Unsupervised principal component analysis (PCA) score plot of individual rabbit multi-parametric profiles. Dimension 1 (Dim1) accounts for 48% and Dimension 2 (Dim2) for 9.7% of total variance. Small circles represent individual animals; large filled circles represent group centroids, each surrounded by its 95% confidence ellipse (Extract 400, grey; Extract 800, yellow; Neomycin, blue; Normal, green; Untreated, orange). (B) Bar plot of the top 10 parameters contributing to Dim1, expressed as percentage contribution; the dashed red line indicates the theoretical uniform contribution threshold (≈ 2.17%). The Variable Contribution analysis (Fig 10B) further highlighted the primary variables associated with the spatial distribution across the dimensions. The clustering trends observed in the PCA map were heavily influenced by coordinates related to bacterial clearance kinetics (load at Days 10, 12, and 13) and systemic inflammatory markers (WBC and CRP). While these variables exhibited the highest contribution scores along Dim1, these mathematical relationships remain exploratory in nature. In small-cohort designs, individual biological variation can heavily influence variable contribution weights. Thus, these parameters should be viewed as hypothesis-generating indicators, pointing to pathogen eradication and the subsequent quenching of the systemic leukocyte response as key therapeutic pathways of the extract rather than validated predictive biomarkers. Comparative functional efficacy and therapeutic parity A comparative functional analysis was conducted between the high-dose extract (800 mg/kg) and the Neomycin standard to evaluate the clinical viability of the combination of the T. diversifolia and P. guajava intervention as a sustainable alternative to conventional therapy (Fig 11). Comparative efficacy of the 800 mg/kg combined extract dose versus the reference antibiotic neomycin on Day 7 post-infection. Bar charts comparing mean ± standard error of the mean (SEM) values for the 800 mg/kg combined-extract group (yellow, n = 4) and the neomycin, 10 mg/kg group (grey, n = 4) across three physiological domains: antioxidant markers (caecal and ileal catalase, malondialdehyde (MDA) and superoxide dismutase (SOD)); the acute-phase marker C-reactive protein (CRP, ng/mL); and the hematological marker white blood cell count (WBC, × 103/µL). Groups were compared for each parameter using an unpaired two-tailed t-test (or the non-parametric equivalent where normality assumptions were not met; GraphPad Prism v8.0.1). Note: No statistically significant differences (P > 0.05) were observed between the two groups for any parameter shown, indicating comparable recovery at these specific endpoints. This finding is limited to the parameters tested and should not be interpreted as evidence of overall clinical, pharmacokinetic, or safety equivalence (see Discussion, Limitations of the Study). The restorative capacity of the P. guajava and T. diversifolia combination was found to be functionally equivalent to Neomycin across all oxidative stress indices. In both the caecum and ileum, the 800 mg/kg cohort exhibited a robust recovery of SOD and CAT activities, with mean values statistically indistinguishable from the antibiotic-treated group (P > 0.05). In terms of immunomodulation, the extract achieved complete systemic stabilization. The suppression of CRP, a sensitive marker of acute-phase inflammation, in rabbits, and the normalization of WBC counts showed no significant divergence between the combined extract of P. guajava and T. diversifolia and Neomycin cohorts. This suggests that the extract possesses a systemic anti-inflammatory mechanism comparable to the resolution achieved through bacterial clearance by synthetic antimicrobials. By resolving the E. coli challenge through both direct antimicrobial action and active tissue repair, the 800 mg/kg dose demonstrated therapeutic efficacy comparable to that of Neomycin. These findings suggest that this combined P. guajava and T. diversifolia extracts could be a potent bioactive agent, an alternative to conventional antibiotic that can maintain rabbit health and productivity. Histopathology results Effect of combined extract on the renal architecture The protective effect of the P. guajava and T. diversifolia combination on the renal microarchitecture of E. coli-infected rabbits is presented in Fig 12. Microscopic examination of the kidney sections from the healthy control group (T0) revealed a well-preserved renal parenchyma. This was characterized by a distinct glomerular architecture (G) with a clear Bowman’s space (US) and clearly differentiated proximal (PT) and distal (DT) convoluted tubules, indicating normal physiological filtration and reabsorption functions. Photomicrographs of rabbit kidney sections following Escherichia coli challenge and treatment with the combined Psidium guajava and Tithonia diversifolia extracts (hematoxylin and eosin (H&E) stain; original magnification ×100; scale bar = 10µm). T0, uninfected control receiving distilled water only (normal control); T1, infected, untreated (vehicle control); T2, infected, treated with neomycin (10 mg/kg bw); T3 and T4, infected, treated with the combined extract at 400 and 800 mg/kg bw, respectively; T5, uninfected, cyclophosphamide-only (immunosuppressed) control. n = 4 kidneys examined per group; one representative field is shown per group. Abbreviations: Cd, cell degeneration; US, urinary space; G, glomerulus; IL, leukocyte infiltration; DT, distal convoluted tubule; PT, proximal convoluted tubule. Note: Histopathological evaluation was descriptive/qualitative, performed by a blinded pathologist; semi-quantitative lesion scoring was not performed in the present study (see Discussion, Limitations of the Study). In contrast, the infected-untreated cohort (T1) exhibited significant histopathological derangement. The infection induced a localized inflammatory response marked by conspicuous leukocyte infiltration (IL) and mesangial expansion within the glomerulus. These alterations are indicative of acute renal distress and the systemic inflammatory burden caused by the pathogenic E. coli strain. However, therapeutic intervention with the combined P. guajava and T. diversifolia extracts effectively mitigated these structural damages. The renal sections from the T3 (400 mg/kg) and T4 (800 mg/kg) groups, alongside the Neomycin-treated cohort (T2), demonstrated a restoration of the renal tissue architecture. While the 800 mg/kg dose (T4) showed minor residual leukocyte infiltrates, the overall prevention of mesangial expansion and tubular disruption confirms the extract’s nephroprotective potential. This structural preservation is consistent with the biochemical results, where the extract successfully normalized serum creatinine and uric acid levels, confirming that the formulation prevents the acute kidney injury (AKI) typically associated with severe colibacillosis. Protective effect of extracts on hepatic microarchitecture The histological evaluation of the liver (Fig 13) confirms the organoprotective properties of the combination of P. guajava and T. diversifolia during acute E. coli infection. Microscopic analysis of the liver from the healthy control group (T0) showed a classical hexagonal lobular arrangement with a well-preserved hepatic parenchyma. The sections exhibited a distinct portal triad comprising the hepatic portal vein (PV), hepatic artery (HA), and bile canaliculus (BC) surrounded by radiating cords of well-defined, polyhedral hepatocytes (He) with prominent nuclei. Photomicrographs of rabbit liver sections following Escherichia coli challenge and treatment with the combined Psidium guajava and Tithonia diversifolia extracts (hematoxylin and eosin (H&E) stain; original magnification ×100; scale bar = 10 µm). Group designations (T0–T5) are as defined in the Fig 12 legend; n = 4 livers examined per group; one representative field is shown per group. Abbreviations: Cd, cell degeneration; He, hepatocytes; HA, hepatic artery; PV, portal vein; BC, bile canaliculus; IL, leukocyte infiltration. Note: Histopathological evaluation was descriptive/qualitative (see Fig 12 legend and Discussion, Limitations of the Study). In the infected-untreated cohort (T1), the hepatic architecture was compromised by a localized inflammatory response, characterized by significant leukocyte infiltration (IL). This infiltration suggests that the systemic E. coli infection induced a degree of hepatitis or endotoxin-mediated tissue stress. However, administration of the combined P. guajava and T. diversifolia extracts formulation at both 400 mg/kg (T3) and 800 mg/kg (T4) successfully mitigated these inflammatory changes. The hepatic sections of the treated groups showed a restoration of the hepatocellular cords and a marked absence of inflammatory clusters, appearing histologically comparable to the Neomycin-treated (T2) and healthy control (T0) groups. This structural preservation directly correlates with the enzymatic profiles discussed earlier; by preventing the infiltration of inflammatory cells and maintaining the integrity of the hepatocellular membranes, the extract effectively prevented the leakage of transaminases (AST and ALT) into the systemic circulation. These findings reinforce the dual role of the combination of P. guajava and T. diversifolia as both an antimicrobial and a potent hepatoprotective agent. Restorative effects of extracts on intestinal (Caecal) microarchitecture The impact of the E. coli challenge and the subsequent therapeutic intervention on the caecal microarchitecture is presented in Fig 14. Histological analysis of the caecal sections from healthy control rabbits (T0) revealed a robust and well-organized intestinal wall. The architecture followed a classic structural hierarchy, consisting of the serosa (Se), muscular layer (Mus), submucosa (Smu), and a well-developed mucosa (Mu) lining the intestinal lumen (Lu). Photomicrographs of rabbit small intestine sections following Escherichia coli challenge and treatment with the combined Psidium guajava and Tithonia diversifolia extracts (hematoxylin and eosin (H&E) stain; original magnification ×100; scale bar = 10 µm). Group designations (T0–T5) are as defined in the Fig 12 legend; n = 4 intestinal segments examined per group; one representative field is shown per group. Abbreviations: Cd, cell degeneration; Lu, intestinal lumen; Mu, mucosa; Smu, submucosa; Mus, muscularis; Se, serosa. Note: Villus height and crypt depth were not measured quantitatively; evaluation was descriptive/qualitative (see Fig 12 legend and Discussion, Limitations of the Study). In the infected-untreated cohort (T1), the E. coli challenge induced severe mucosal degeneration. The sections exhibited a distinct narrowing of the intestinal mucosa and marked villous atrophy. This loss of structural height and complexity in the mucosal layer indicates a depletion of goblet cell function (leading to decreased mucus secretion) and a reduction in the total absorptive surface area. Such morphological damage provides a structural explanation for the persistent diarrhoea and negative growth performance observed in structurally comparable to the healthy controls and the Neomycin-treated cohort (T2). By maintaining the mucosal barrier and preventing villous blunting, the high-dose extract (800 mg/kg) preserved the intestinal function, facilitating nutrient absorption and preventing the translocation of enteric pathogens. This structural recovery serves as the biological foundation for the observed resolution of clinical diarrhoea and the restoration of the animals’ growth trajectory. Discussion Even though rabbit meat continues to be considered a niche product, demand for it is increasing steadily in various parts of the world, particularly in Asia [26]. Beyond this expanding market, rabbit farming also offers advantages in social equity [27] and environmental sustainability [2]. Despite this potential, the industry, especially in developing nations, is severely constrained by enteric pathologies, most notably colibacillosis caused by pathogenic strains of E. coli. This disease compromises animal health and productivity through high morbidity and mortality, and poses a critical One Health risk because the transmission of MDR strains through the food chain represents a growing public health threat [28,29]. As the efficacy of conventional antimicrobials wanes with the global rise of AMR, the exploration of plant-based therapeutic alternatives has become a pharmacological necessity. Our previous ethnopharmacological screening of Cameroonian flora identified P. guajava and T. diversifolia as potent inhibitors of pathogenic E. coli, with their combination exhibiting a synergistic reduction in Minimum Inhibitory Concentration of up to 64-fold [19]. Building on that in vitro evidence, the present study evaluated the in vivo curative potential and systemic restorative effects of the combined P. guajava and T. diversifolia extract in E. coli-infected rabbits. The therapeutic efficacy of the combined extract was assessed in colibacillosis-infected rabbits, following the induction protocol of Pouofo et al. [30]. The treatment was conducted for 7 days, during which the bacterial shedding was used to monitor the treatment. By the end of the treatment period, the various parameters evaluated to determine the extract’s therapeutic efficacy, including body weight, relative organ weight, bacterial shedding, haematological, biochemical, inflammatory, and oxidative markers, as well as histopathological findings, showed comparable values between T5 (immunosuppression group) and the healthy control group T0 (uninfected, untreated, and free of cyclophosphamide/streptomycin). This finding indicates that the immunosuppressive effect of cyclophosphamide was reversible and had no measurable lasting impact under our experimental conditions. Therefore, the variation observed in the infected groups could be attributed to the infection and/or extract treatment rather than to pretreatment toxicity. The experimental induction of colibacillosis produced a profound clinical decline in the untreated cohort, characterized by acute weight loss, dehydration, and high-titer fecal shedding of Congo red–positive E. coli. This pathological state is consistent with the capacity of pathogenic E. coli to disrupt intestinal water transport and induce catabolic stress [31]. The reversal of these symptoms following administration of the combined extract, particularly at 800 mg/kg demonstrates clear therapeutic efficacy. Bacterial clearance by Day 5 of treatment by combined extract is notable and comparable to the fast-killing activity observed with Neomycin. This bacterial clearance is consistent with previously observed antimicrobial activity of these extracts and their combination [19,32]. Our LC-MS/MS profiling of the two extracts identified pedunculagin, an ellagitannin, in P. guajava, together with the flavonoid’s quercetin, quercetin-4′-O-glucoside, myricetin-3-O-pentoside, and 2′-hydroxy-α-naphthoflavone in T. diversifolia (S8 Table in S1 File). In fact, tannins and flavonoids of P. guajava have been reported to interact with bacterial cell-wall proteins and inhibit E. coli growth. Dhiman et al. [33], showed that the methanolic extract P. guajava leaf exhibited antibacterial activity against E. coli with a minimum inhibitory concentration of 0.78 μg/ml and minimum bactericidal concentration of 50 μg/ml and the phytochemical screening revealed flavonoids, steroids, and tannins as the likely antimicrobial contributors. However, Pereira et al. [34] also found that an aqueous P. guajava leaf extract, contain flavonoid and tannin classes (rutin, hesperidin, quercetin). Recently, El-Deeb et al. [32] conducted a comprehensive assessment of P. cattleianum aerial-part polyphenols and found that, beyond producing significant antidiarrheal effects in a castor oil-induced diarrhoea model, the extract also showed direct activity against several diarrhoea-associated pathogens, with in silico docking implicating the bacterial fatty-acid synthesis enzyme FabH and the kappa opioid receptor as plausible molecular targets. An independent chemical characterization of an aqueous leaf extract of T. diversifolia by Dongmo et al. [35] reported tannins and flavonoids, together with phenols, alkaloids, terpenoids, and saponins, thereby supporting the findings of our metabolomics annotation.. The septic hemogram observed in the untreated group, marked by leucocytosis, thrombocytosis, and secondary anaemia, reflects the systemic inflammatory burden of colibacillosis, consistent with findings reported by Petrov et al. [36] in both spontaneous and experimental colibacillosis in weaned rabbits. The normalization of these parameters in all treated groups (T2–T4) indicates resolution of systemic stress. The extract lowered circulating TNF-α, IL-6, and IL-1β and returned CRP to near-normal levels, consistent with an immunomodulatory rather than a purely immunosuppressive action. Phytochemicals from both plant sources may plausibly contribute to this effect. Recent evidence from a carrageenan-induced inflammation study in Wistar rats provides strong support for the anti-inflammatory potential of P. guajava. In that study, an ethanolic bark extract significantly reduced TNF-α, IL-6, and CRP levels compared with those observed in untreated controls. Molecular docking analysis further suggested that constituents of the extract may interact with proteins involved in inflammatory pathways [37]. In carrageenan-induced inflammation models, Broering et al. reported that an extract of T. diversifolia reduced the secretion of TNF, IL-1β, IL-6, and nitrite, while also inhibiting neutrophil chemotaxis and CD18 expression [38]. However, specific mechanisms such as NF-κB inhibition, direct cytokine receptor modulation, ROS scavenging, membrane stabilization, or inhibition of bacterial adhesion were not directly evaluated in the present study, therefore remain as plausible literature-supported hypotheses rather than demonstrated mechanisms. Unlike antibiotics, which primarily target the pathogen, this combined extract of P. guajava and T. diversifolia actively manages the host’s immune response, preventing the tissue-damaging effects of chronic inflammation. The hypoproteinaemia and hypoalbuminemia observed in Group T1 are consistent with a negative acute-phase response, in which the liver shifts protein synthesis toward inflammatory mediators such as CRP at the expense of albumin [39], a pattern previously reported in E. coli infection [40,41]. The concurrent rise in AST and GGT points to hepatocellular leakage, while elevated uric acid suggests impaired renal clearance or accelerated purine catabolism secondary to tissue damage. The extract’s ability to restore these metabolic markers, corroborated by our histological findings of preserved portal triad architecture and tubular integrity, is consistent with a hepatoprotective and nephroprotective effect [42]. At the primary site of infection, colibacillosis-induced oxidative stress (elevated MDA, depleted SOD/CAT) plausibly drove the mucosal damage observed histologically, with villous atrophy and mucosal narrowing providing a physical basis for the malabsorption seen in untreated animals. The tannins and flavonoids identified in both extracts are consistent with a protective, astringent mechanism in which these compounds could coat and stabilize the mucosal surface, limiting further epithelial damage. That could plausibly contribute to the restored villous height and mucosal thickness observed in treated groups [43]. This mechanism was not directly tested in the present study and remains a hypothesis consistent with the compositional and histological findings. The multivariate analyses (PCA and hierarchical clustering) show that, within this exploratory dataset, the 800 mg/kg dose cohort clusters closer to the healthy and Neomycin-treated groups than to the untreated group. Given the small per-group sample size (n = 4) relative to the number of variables analysed, and the absence of an independent validation cohort, these multivariate results should be interpreted as purely descriptive. Overall, the combined extract shows antimicrobial, immunomodulatory, antioxidant, and organ-protective effects comparable to Neomycin at 800 mg/kg, supporting further mechanistic and pharmacokinetic investigation as a candidate alternative for colibacillosis management. Limitations of the study The chemically induced infection model (cyclophosphamide + streptomycin) is a manipulated, opportunistic model rather than a natural infection; the T5 control indicates pretreatment effects had resolved by the study endpoint, but early interactions between immunosuppression and infection remain a confounding variable that non-chemical, age-susceptible models could better address. The chemically induced infection model (cyclophosphamide + streptomycin) is a manipulated, opportunistic model rather than a natural infection; the T5 control indicates pretreatment effects had resolved by the study endpoint, but early interactions between immunosuppression and infection remain a confounding variable that non-chemical, age-susceptible models could better address. The small sample size (n = 4–5/group), while adequately powered for the large primary effects observed (a priori Cohen’s f ≥ 0.70, power = 0.80), limits detection of subtler effects and may not capture the full range of biological variability in outbred rabbits. The small sample size (n = 4–5/group), while adequately powered for the large primary effects observed (a priori Cohen’s f ≥ 0.70, power = 0.80), limits detection of subtler effects and may not capture the full range of biological variability in outbred rabbits. Histopathological evaluation was qualitative, without semi-quantitative lesion scoring or morphometric measurement (villus height, crypt depth), due to equipment constraints; the polarized group differences were visually clear but not numerically graded. Histopathological evaluation was qualitative, without semi-quantitative lesion scoring or morphometric measurement (villus height, crypt depth), due to equipment constraints; the polarized group differences were visually clear but not numerically graded. PCA/heatmap analyses are exploratory given the sample-to-variable ratio and lack an independent validation cohort. PCA/heatmap analyses are exploratory given the sample-to-variable ratio and lack an independent validation cohort. Mechanistic claims regarding NF-κB inhibition, receptor binding, membrane disruption, or adhesion inhibition are hypotheses drawn from phenotypic and phytochemical data, not directly tested pathways; future work (bioactivity-guided fractionation, adhesion assays, pharmacokinetics, dedicated toxicology, and non-chemical infection models) is needed to confirm them. Mechanistic claims regarding NF-κB inhibition, receptor binding, membrane disruption, or adhesion inhibition are hypotheses drawn from phenotypic and phytochemical data, not directly tested pathways; future work (bioactivity-guided fractionation, adhesion assays, pharmacokinetics, dedicated toxicology, and non-chemical infection models) is needed to confirm them. Conclusion The present study demonstrates the in vivo efficacy of the combined P. guajava and T. diversifolia extracts in mitigating E. coli infection in a rabbit model. In infected, immunocompromised rabbits, the combined extract at 800 mg/kg was associated with resolution of the clinical signs of colibacillosis, including restored body-weight gain and a reduction in faecal bacterial shedding to near-undetectable levels, alongside repair of infection-induced tissue damage and no overt signs of toxicity within the parameters assessed in this study. Treated animals showed biochemical, haematological, and antioxidant profiles approaching those of healthy controls, though consistent with the exploratory nature of our multivariate analysis this should be read as a marked improvement toward baseline rather than confirmed physiological equivalence. These findings indicate that the combined P. guajava–T. diversifolia extract is a promising candidate for managing colibacillosis in rabbits, warranting further development. By addressing both the pathogen and the host’s systemic response, this combination represents a potentially sustainable approach to colibacillosis control amid rising antimicrobial resistance, consistent with One Health-aligned veterinary practice. Before translational application, several steps remain. Phytochemical fingerprinting and standardization of the formulation are needed to support pharmacological interpretation and reproducibility. Evaluation against a broader panel of multidrug-resistant strains would clarify the extract’s relevance to other enteric infections, and 16S rRNA metagenomic profiling would clarify its impact on commensal intestinal microbiota relative to conventional aminoglycosides. Critically, dedicated pharmacokinetic, dose-optimization, and long-term toxicology studies, together with larger confirmatory trials, are required before the clinical or field-level viability of this formulation can be established. Supporting information This supporting information provides comprehensive data related to the antibacterial and therapeutic potential of combined aqueous extracts of Psidium guajava (bark) and Tithonia diversifolia (leaves) in a rabbit model of colibacillosis. Fig S1 shows red-pigmented colonies on the Congo Red binding assay (CR+), indicating biofilm formation. Table S1 details the API 20E biochemical profile used to confirm the identity of the isolated E. coli strain. Tables S2 and S3 present the in vivo efficacy data, illustrating the effects of the combined extracts on body weight variation and the dynamics of faecal E. coli shedding over time. Tables S4 and S5 evaluate the physiological impact of treatments by measuring oxidative stress biomarkers and haematological parameters, respectively. Table S6 reports the immunomodulatory effects by quantifying cytokine levels (TNF-α, IFN-γ, IL-10, IL-6, IL-1β, and CRP). Table S7 provides key biochemical parameters (ALAT, ASAT, GGT, triglycerides, cholesterol, HDL, and LDL) to assess hepatic and metabolic function. Finally, Table S8 presents the LC‑MS/MS phytochemical profiling, listing putatively annotated compounds from both plant extracts, including their retention times, molecular formulae, molecular weights, and compound classes. All quantitative data are expressed as mean ± SEM, with statistical significance denoted as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. (DOCX) 4 Jun 2026 Dear Dr. Boyom, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 19 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Seth Agyei Domfeh, PhD Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE’s style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. As part of your revision, please complete and submit a copy of the Full ARRIVE 2.0 Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: https://arriveguidelines.org/sites/arrive/files/documents/Author%20Checklist%20-%20Full.pdf Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article. 3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewer’s Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** Reviewer #1: The manuscript is interesting but some corrections need to be addressed. The volume of the bacterial suspension for induction should be included. Also, the software used for data analysis should also be included. The term polyherbal extract should be replaced with the combined extract of ....... Moreso, The preparation of the combined extract should be included, and how the doses for the experiment was determined (It seems high). Most sentences should start appropriately, avoid starting sentence with 'to,by' . The explanations of the results obtained do not reflect the results or experiments done. There is alot of overstatement. The conclusion should be written to reflect the work done, be it for the abstract and the entire manuscript. Authors should rewrite the manuscript reflecting the results obtained. So figures are confusing to the understanding of the audience. The manuscript has some indications and has been highlighted. Reviewer #2: 1. There are some grammatical, alignments and typographical errors are noted in the manuscript and it should be thoroughly checked and corrected throughout the manuscript. 2. The use of abbreviations in the abstract may distract readers who wish to quickly skim through several publications before deciding to read one in full. It may therefore help to write out terms fully in abstract (For example, AST). 3. Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears first time in the abstract and the remaining for the text and then use only the abbreviation (For example, IL-1β, IL-6, superoxide dismutase (SOD), etc.,). Make a word abbreviated in the article that is repeated at least three times in the text, not all words to be abbreviated. 4. The full form of the species should be given when the first time appears in both the abstract and in the remaining part of the manuscript and it should be followed by only the first letter of the genus (For example, Psidium guajava / Tithonia diversifolia when the first time appear and followed by P. guajava / T. diversifolia) and this should be checked all other species used in the manuscript. 5. The time (season) of collection of this species should be added. As it is well-known that one of the factors affecting the constituents, is the time of collection, so please give top priority to this issue. 6. The authors may include the details of the quantity of fresh sample used and the quantity of the powder obtained (the ratio between fresh plant and powder) under the heading materials and methods. 7. The standard diet used in the present investigation should also be included with its composition and source of the same. 8. In the materials and methods, the authors may cite references for standard protocol, manufacture instructions, if reference is given with it and the same should be added in the reference section. 9. The authors may justify how the dose optimized for the present investigation in the materials and methods (either based on available literature or previous study). If from the others study should be supported with reference. 10. The authors should mention the following when referring to GraphPad Prism version 8.0.1 (GraphPad Software, San Diego, CA, USA). 11. The auhors should be given necessary expansion in the figure legend, for example, MDA, SOD, CAT, and GSH. 12. The conclusion provides a comprehensive overview of the work, but it could be a bit more realistic based on the evidence of the results for better understanding of the outcome of the present investigation. Moreover, the authors may also include the limitation of the present findings for a better understanding of the manuscript. Reviewer #3: Evaluation of the manuscript entitled “A Combined Aqueous Extract of Psidium guajava and Tithonia diversifolia Restores Metabolic Homeostasis and Intestinal Integrity in Experimental Rabbit Colibacillosis” ID: PONE-D-26-07694 The manuscript investigates the therapeutic efficacy of a combined herbal extract in an experimentally induced rabbit colibacillosis model. The study addresses an important topic regarding increased incidence of antimicrobial resistance and the search for alternative veterinary therapeutics. The manuscript includes microbiological, biochemical, hematological, immunological, antioxidant, and histopathological evaluations. However, there are several major methodological and scientific concerns, particularly regarding the in vivo study design, characterization of the infection model, extract standardization, statistical analysis, and interpretation of the results. Major comments: A) The rationale for choosing the infection model and experimental design 1. The authors induced infection after administering both cyclophosphamide and streptomycin prior to E. coli inoculation. This creates a highly artificial model of disease but: Are the observed pathological changes truly due to E. coli infection, or partially due to cyclophosphamide-induced immunotoxicity and streptomycin-induced dysbiosis? Clearly explain the rationale for combining cyclophosphamide and streptomycin. 2. The manuscript includes an “immunosuppression control” group (T5), without mentioning a sufficient description of the treatment regimen: The authors should: • Clarify whether T5 received cyclophosphamide alone or both cyclophosphamide and streptomycin, • Provide complete data and discussion for T5. 3. The authors need to discuss the limitations of this highly manipulated infection model as cyclophosphamide itself can induce several effects like oxidative stress, hematological changes, and organ toxicity. Accordingly, several reported outcomes may not solely reflect colibacillosis. B) Lack of phytochemical characterization and extract standardization The major weakness of the study is the absence of phytochemical profiling and standardization of the two used extracts. The authors repeatedly referred the biological effects to the presence of flavonoids, tannins, and sesquiterpene lactones, with NF-κB modulation, without quantification and characterization of the present compounds using, for example, HPLC, LC-MS/MS, total phenolic/flavonoid quantification, or identification of the major compounds, including chromatographic fingerprinting. Otherwise, mechanistic claims should be toned down substantially. C) Small sample size and statistical power concerns The study used only n = 5 rabbits/group, with one mortality in the untreated infected group and only four animals/group ultimately analyzed histologically and biochemically. The endpoints measured are quite large in comparison with the number of animals per group. Accordingly, The authors should: • provide statistical power justification, • clarify whether normality testing was performed, • explain how multiple testing inflation was controlled, • and discuss the limitations imposed by the small sample size. D) Absence of quantitative histopathology evaluation The histopathological analysis is entirely descriptive mentioning “leukocyte infiltration, villous atrophy, restoration,” etc. However, no histological scoring system was used, and no semi-quantitative analysis was provided. The authors should: introduce validated histopathological scoring systems, quantify inflammatory infiltration and villus height/crypt depth, and provide lesion severity scores. E) Cytokine and mechanistic claims are overstated The authors repeatedly conclude that the extracts used caused NF-κB inhibition, immunomodulation, ROS scavenging mechanisms, membrane stabilization, and bacterial adhesion inhibition, without experimental evaluation of these pathways. Only general screening parameters were measured. Mechanistic statements should be rewritten more cautiously and presented as hypotheses rather than demonstrated mechanisms. For example: “may involve modulation of inflammatory pathways” instead of: “likely mediated through NF-κB inhibition.” F) Important missing methodological details Several experimental details are insufficiently described, including: 1. Randomization: The manuscript states rabbits were “randomly assigned,” but the randomization method is not described. 2. Blinding: No mention of blinding during treatment administration, histological evaluation, or data analysis. 3. Sex distribution: The rabbits were “mixed sex,” but the distribution per group was not provided. Sex-dependent differences may influence immune response. 4. Extract formulation: The exact ratio between the two combined extracts is not clearly stated. 5. Dose justification: The rationale for the selected doses is not mentioned G) Bacterial characterization is insufficient The isolate was identified only by API 20E and Congo red binding assay. However, the study repeatedly refers to EPEC, virulence, pathogenicity, attaching/effacing lesions. No molecular confirmation of virulence genes was performed. The authors should avoid definitive classification as EPEC unless molecular virulence markers are confirmed, or include PCR confirmation for relevant virulence genes. H) PCA and multivariate analysis appear overinterpreted The PCA and heatmap analyses are visually attractive, but the sample size is extremely small, the number of variables is very large, and no validation strategy is described. Statements such as: “biological reset” and “systemic recovery indistinguishable from healthy baseline” are exaggerated considering the exploratory nature of PCA. The authors should moderate interpretation, clarify variance explained, and discuss limitations of multivariate modeling with small datasets. I) Discussion parts after each results section need references and referral to the literature The discussion following several results sections lacks sufficient referencing and critical comparison with the literature. The authors should discuss their findings in relation to previous studies, emphasizing agreements, discrepancies, possible explanations, and remaining research gaps. For example, Psidium species records indicate antidiarrheal activity through antimicrobial effects, not only for tannins (DOI: https://doi.org/10.1016/j.jep.2025.119670) Minor Comments 1. Several sections contain overly promotional language inappropriate for scientific writing, including: • “biological reset,” • “high-activity extract,” • “profound therapeutic trajectory,” • “gold-standard treatment,” • “extinguishing inflammatory cascades.” The manuscript should include a more objective scientific tone. 2. The discussion is excessively long and repetitive. Several statements restate results instead of critically interpreting them (back to comment no. I in the major comments). 3. The authors should clarify whether ALT and AST units, cytokine units, and oxidative stress marker units, were standardized and validated for rabbit samples (ensure the kits are valid for rabbit samples). 4. Figure legends appear insufficiently detailed. They should be revised to be self-interpreted in some sections through including: • magnification, • stain details, • scale bars, • and statistical annotations. 5. The ARRIVE guideline adherence is mentioned, but several ARRIVE-required elements remain incomplete: • sample size justification, • exclusion criteria, • blinding details. 6. The conclusion somewhat overstates translational applicability. The statement that the extract is “clinically equivalent to conventional aminoglycosides” is not fully supported without pharmacokinetics, toxicity studies, dose optimization, long-term safety, and field validation. Accordingly, the conclusion must be revised. The work should not be accepted in its current form, but it may become suitable for publication after major methodological clarification, further specific analysis, and thorough revision of the interpretation and presentation of the data. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Dr. A. Vijaya Anand Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: PONE-D-26-07694 Revised Dr Zeukoo.pdf Submitted filename: PONE-D-26-07694.docx 20 Jul 2026 Response to Reviewers' Comments Comments reviewers and editor: We thank the Editor and the three Reviewers for their constructive evaluation of our manuscript. Based on they inputs and recommendations, we have revised the entire manuscript, remade all figures and figure captions. Below, we tried to the best of our ability to respond point-by-point to every comment. Reviewer comments are reproduced in bold italics; our responses follow in red. Slight change in the title: The original title was revised to align with the revised manuscript. The new title is: A Combined Aqueous Extract of Psidium guajava L. and Tithonia diversifolia (Hemsl.) A. Gray Improves Metabolic Homeostasis and Preserves Intestinal Integrity in Experimental Rabbit Colibacillosis Manuscript ID: PONE-D-26-07694 Reviewer #1 The manuscript is interesting, but some corrections need to be addressed. Comment 1: The volume of the bacterial suspension used for induction should be included. Response 1: The disease was induced by administering 1 mL /100 g of body weight of bacterial suspension, adjusted to a 109 CFU/mL in 0.9% saline. This information has been added to the Materials and Methods section. Comment 2: The software used for data analysis should also be included. Response 2: Data were analysed using GraphPad Prism and OriginPro, and multivariate analysis was performed in the R environment. This information has been added to the corresponding Methods section (see also Reviewer #2, Comment 10, for the full software citation). Comment 3: The term “polyherbal extract” should be replaced with “the combined extract of …”. Response 3: The term “polyherbal extract” has been replaced throughout the manuscript with “the combined Psidium guajava and Tithonia diversifolia extracts,” as suggested. Comment 4: The preparation of the combined extract should be described, and the rationale for the doses used in the experiment should be explained (the doses appear high). Response 4: The preparation of the combined extract has been fully described in the Methods section. Briefly, the two extracts were combined in a 96.975% P. guajava : 3.025% T. diversifolia ratio (w/w), determined from the synergistic Fractional Inhibitory Concentration Index (FICI = 0.265) established in our prior in vitro work (Chouegouong et al., 2023; doi:10.1007/s13596-021-00615-1). Fresh stock solutions were prepared daily in sterile distilled water at 40 mg/mL and 80 mg/mL to deliver 400 and 800 mg/kg bw, respectively. The administration was done by oral gavage at a fixed volume of 10 mL/kg bw (i.e., 387.9 mg/kg P. guajava + 12.1 mg/kg T. diversifolia for the low dose, and 775.8 mg/kg P. guajava + 24.2 mg/kg T. diversifolia for the high dose). The selected doses (400 and 800 mg/kg bw) are consistent with standard pharmacological evaluations of crude phytotherapeutic agents in lagomorph models, as previously reported by Hirudkar et al. (2020); this rationale, together with the full preparation protocol, has been added to the Methods section. Comment 5: Most sentences should be structured appropriately; sentences should not begin with “to” or “by”. Response 5: Constructions beginning with “To” or “By” have been revised throughout the manuscript to improve phrasing and fluency. Comment 6: The explanations of the results obtained do not accurately reflect the results or experiments performed; there is considerable overstatement. Response 6: The results section has been rephrased to remove overstatement and to ensure that the interpretations presented are directly supported by the data obtained. Comment 7: The conclusion should be rewritten to accurately reflect the work done, both in the abstract and throughout the manuscript. Response 7: The conclusion has been rewritten in both the abstract and the main text to align precisely with the results obtained (see also Reviewer #2, Comment 12, and Reviewer #3, Minor Comment 6). Comment 8: The manuscript should be rewritten to better reflect the results obtained; the figures are confusing for the reader. Response 8: The manuscript has been revised to better reflect the data generated, all figures are now explicitly cited and described within the text, and every figure legend has been rewritten to be self-contained and self-interpretable (see the accompanying Revised Figure Legends document, and Reviewer #2, Minor Comment 4). Comment 9: The manuscript contains some inconsistencies, which have been highlighted. Response 9: Thank you to all reviewers for flagging these inconsistencies. We have revised the entire manuscript and checked all results individually against the raw data and corrected; the corresponding changes are marked in the revised manuscript. Reviewer #2 Comment 1: Some grammatical, alignment, and typographical errors are noted in the manuscript; it should be thoroughly checked and corrected throughout. Response 1: We thank the Reviewer for this observation. We have carefully re-read the entire manuscript and performed a thorough revision to correct all grammatical, alignment, and typographical errors identified. Comment 2: The use of abbreviations in the abstract may distract readers who wish to quickly skim several publications before deciding to read one in full. It may help to write terms out in full in the abstract (for example, AST). Response 2: We have revised the abstract to write out all abbreviated terms in full. Comment 3: Abbreviations should be checked throughout the manuscript: the full term should be introduced at first mention in the abstract and again at first mention in the main text, after which only the abbreviation should be used (for example, IL-1β, IL-6, superoxide dismutase (SOD), etc.). Only terms repeated at least three times in the text should be abbreviated. Response 3: We have thoroughly reviewed all abbreviations throughout the manuscript, introducing each full term at first mention before subsequent use of the abbreviation, and removing abbreviations for terms that did not meet the repetition threshold. The corresponding revisions have been incorporated into the updated manuscript and into the revised figure legends (see accompanying document). Comment 4: The full species name should be given at first mention in both the abstract and the main text, followed thereafter by the abbreviated genus initial (for example, Psidium guajava / Tithonia diversifolia at first mention, followed by P. guajava / T. diversifolia); this should be checked for all species used in the manuscript. Response 4: We have revised the entire manuscript and edited the full species of the two plants. Comment 5: The time (season) of collection of the plant species should be added, since the collection period is known to affect phytochemical constituents; this should be given top priority. Response 5: We completely agree with the reviewer that transparency in botanical processing is fundamental for reproducibility. We have now updated the "Ethnobotanical Selection and Extract Preparation" section to include the exact exact collection dates and season for both plant species, the starting fresh weights, resulting dry powder weights, and calculated fresh-to-dry ratios for both species. Comment 6: The quantity of fresh plant material used and the quantity of powder obtained (i.e., the fresh-to-powder ratio) should be included under Materials and Methods. Response 6: We have added the quantities of fresh plant material and the corresponding dry powder yield to the Materials and Methods section. Comment 7: The standard diet used in the study should be described, including its composition and source. Response 7: Information regarding the composition of the standard diet has been incorporated into the revised manuscript. Comment 8: In the Materials and Methods, references should be cited for any standard protocols or manufacturer instructions used, and the corresponding citations should be added to the reference list. Response 8: The Methods section has been updated to include references for the standard protocols used, and the corresponding citations have been added to the reference list. Comment 9: The dose selected for the present study should be justified in the Materials and Methods, either based on the available literature or a previous study; if derived from another study, it should be supported with the appropriate reference. Response 9: The dose justification, supported by the relevant reference (Chouegouong et al., 2023; Hirudkar et al., 2020), has been incorporated into the revised Materials and Methods section (see also Reviewer #1, Comment 4). Comment 10: The authors should cite the software fully when referring to it. GraphPad Prism version 8.0.1 (GraphPad Software, San Diego, CA, USA). Response 10: We have updated the Methods section to include this full software citation. Comment 11: Necessary expansions should be given in the figure legends, for example for MDA, SOD, CAT, and GSH. Response 11: We have rewritten every figure legend so that all abbreviations (including MDA, SOD, CAT and GSH) are expanded at first mention within each individual legend, in line with journal style for self-contained legends. Please see the accompanying Revised Figure Legends document. Comment 12: The conclusion provides a comprehensive overview of the work but could be more realistic in relation to the evidence presented, to better convey the outcome of the investigation. The authors may also wish to include the limitations of the present findings. Response 12: We have revised the conclusion to be more precise and directly grounded in the evidence generated by the present study, and we have added a dedicated statement on the limitations of the study and on future investigations, as recommended (see also Reviewer #3, Comments A–D, H, and Minor Comment 6). Reviewer #3 Major Comments Comment A — Rationale for the infection model and experimental design: The authors induced infection after administering both cyclophosphamide and streptomycin prior to E. coli inoculation. This creates a highly artificial disease model. Are the observed pathological changes truly due to E. coli infection, or are they partly due to cyclophosphamide-induced immunotoxicity and streptomycin-induced dysbiosis? The rationale for combining cyclophosphamide and streptomycin should be clearly explained. Response A1: We thank the Reviewer for raising this critical point. We agree that pretreatment with cyclophosphamide and streptomycin adds complexity to the physiological baseline; however, this combination follows a well-established, highly reproducible methodological precedent for inducing an acute, standardised intestinal E. coli infection in adult rabbits (Nguiam et al., 2021), for two complementary reasons: (1) streptomycin transiently clears the facultative anaerobic Gram-negative gut microflora that would otherwise confer strong colonisation resistance, opening an ecological niche that allows the challenge strain to colonise and proliferate; and (2) cyclophosphamide induces transient immunosuppression that mimics the opportunistic susceptibility seen in young, weanling, or stressed animals in the field, ensuring a reliable, synchronised onset of acute clinical colibacillosis across cohorts. This rationale has been added to the revised Methods section. Addressing Potential Confounding Pathological Changes: To determine whether the pathological changes observed were attributable to the infection itself rather than to the pretreatment, we included a dedicated immunosuppression-only control group (Group T5), which received the same cyclophosphamide pretreatment but was not inoculated with E. coli (see Response A2 below for the exact T5 regimen). By Day 7 post-infection (9 days post-pretreatment), Group T5 showed no significant differences (P > 0.05) from the healthy, untreated control group (T0) in clinical scores, body weight gain, hematological profile, or tissue histopathology, whereas the infected, untreated group (T1) exhibited severe diarrhoea, weight loss, systemic inflammation, and marked histopathological damage. This parity between T5 and T0 indicates that the physiological and immunological perturbations caused by the pretreatment were transient and largely resolved by the study endpoint, supporting the interpretation that the pathology documented in the infected groups reflects the E. coli challenge. We nonetheless agree that the reliance on chemically induced susceptibility is an inherent limitation of this model, and we have added this point explicitly to the new "Limitations of the Study" subsection of the Discussion. Comment - The manuscript includes an “immunosuppression control” group (T5), without a sufficiently detailed description of the treatment regimen. The authors should clarify whether T5 received cyclophosphamide alone or both cyclophosphamide and streptomycin. Response A2: We confirm that Group T5 (Immunosuppression Control) received cyclophosphamide alone and did not receive streptomycin, so as to isolate the biological effects of chemical immunosuppression on hematological profile, oxidative stress, and tissue architecture, independent of antibiotic-induced gut dysbiosis and of the E. coli challenge. We have expanded the Materials and Methods to state explicitly that animals in Group T5 received a single intraperitoneal injection of cyclophosphamide (30 mg/kg bw) 48 hours before the designated infection timeline, did not undergo streptomycin clearance or bacterial inoculation, and received daily oral gavage of vehicle (10 mL/kg bw sterile distilled water) for 7 consecutive days starting 24 hours post-induction, matching the handling stress and administration volume of the treated cohorts. Comment- The authors need to discuss the limitations of this highly manipulated infection model, as cyclophosphamide itself can induce oxidative stress, haematological changes, and organ toxicity. Accordingly, several reported outcomes may not solely reflect colibacillosis. Response A3: We agree that cyclophosphamide is a potent alkylating agent capable of inducing transient myelosuppression, systemic oxidative stress, and organ toxicity, and that this is an important limitation of chemically facilitated infection models. To isolate the contribution of cyclophosphamide from that of the infection, we compared Group T5 (cyclophosphamide alone, uninfected) with Group T0 (healthy control) and Group T1 (infected, untreated). By Day 7 post-infection, the hematological, biochemical, and tissue lipid-peroxidation parameters of Group T5 were statistically indistinguishable from those of Group T0 (P > 0.05), in clear contrast to the severe, persistent leukopenia, systemic inflammation (elevated TNF-α, IL-6, CRP), oxidative stress (elevated MDA; depleted SOD and catalase), and tissue damage observed in Group T1. This indicates that the acute toxicological effects of cyclophosphamide had largely resolved by the time of sample collection, although we agree that early-stage cyclophosphamide toxicity remains a confounding variable and a limitation of the model. A dedicated “Limitations of the Study” subsection has been added to the Discussion, and the T5-versus-T0/T1 comparison is now presented there explicitly to help the reader distinguish the relative contribution of cyclophosphamide from that of the infection. Comment B — Lack of phytochemical characterisation and extract standardisation: The major weakness of the study is the absence of phytochemical profiling and standardisation of the two extracts used. The authors repeatedly attribute the biological effects to the presence of flavonoids, tannins, and sesquiterpene lactones, and to NF-κB modulation, without quantification or characterisation of these compounds (e.g., by HPLC, LC-MS/MS, total phenolic/flavonoid quantification, or chromatographic fingerprinting). Otherwise, the mechanistic claims should be substantially toned down. Response B: Our previous study (Chouegouong et al., 2023) reported the chemical fingerprint of these same two extracts, confirming the presence of several chemical classes, including terpenes, flavonoids, and tannins; this reference has been cited in the revised manuscript. Moreover, we also performer an LC-MS analysis of crude extracts from Psidium guajava L. and Tithonia divers Submitted filename: Response_to_Reviewers_200726 (1).docx 7 Aug 2026 Dear Dr. Boyom, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Seth Agyei Domfeh, PhD Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer’s Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** Reviewer #1: The authors should include the statistical software used in the methods section of the abstract. Also, the sentences starting with to, for, and any, should be constructed appropriately. The graph axis should be checked and labelled.The limitations should be written in point form. The references should be checked and edited, font size checked too. The manuscript has been highlighted. Reviewer #2: 1. This suggestion is not carried out properly and it should be rectified (Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears first time in the abstract and the remaining for the text and then use only the abbreviation). For example, IL-1β, IL-6, C-reactive protein (CRP), superoxide dismutase (SOD), and these types of corrections need to be checked all other abbreviations used in the manuscript. 2. The technical terms (Latin Phrase) "in vitro" should be italic and it should be checked all over the manuscript. Reviewer #3: The authors addressed all the requested comments and edits. The manuscript is suitable to be accepted in PLOS ONE. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Dr. A. Vijaya Anand Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: PONE-D-26-07694_R1 Revised Dr Zeukoo .pdf 11 Aug 2026 Response to Reviewers' Comments Manuscript ID: PONE-D-26-07694R1 Reviewer #1: Comment1: The authors should include the statistical software used in the methods section of the abstract. Response 1: The names of the softwares employed for the data analysis have now been mentioned in the Methods section of the abstract. Comment2: Also, the sentences starting with to, for, and any, should be constructed appropriately. Response 2: The sentences starting with " to, for, and any " have been revised in the entire manuscript. Comment 3: The graph axis should be checked and labelled. The limitations should be written in point form. Response 3: The figures axis was reviewed and revised, and the limitations section written in point form. Comment 4: The references should be checked and edited, font size checked too. The manuscript has been highlighted. Response 4: The references and manuscript formatting, including font size, were carefully checked and corrected according to the journal’s guidelines. Reviewer #2: Comment 1. This suggestion is not carried out properly and it should be rectified (Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears first time in the abstract and the remaining for the text and then use only the abbreviation). For example, IL-1β, IL-6, C-reactive protein (CRP), superoxide dismutase (SOD), and these types of corrections need to be checked all other abbreviations used in the manuscript. Response 1: All abbreviations have been carefully checked and standardized throughout the manuscript. Comment 2. The technical terms (Latin Phrase) "in vitro" should be italic and it should be checked all over the manuscript. Response 2: The expression in vitro, as well as other Latin expressions such as in vivo, has been italicized consistently throughout the manuscript. Submitted filename: Response to Reviewers Comments 10 08 26.doc 25 Aug 2026 A Combined Aqueous Extract of Psidium guajava L. and Tithonia diversifolia (Hemsl.) A. Gray Improves Metabolic Homeostasis and Preserves Intestinal Integrity in Experimental Rabbit Colibacillosis PONE-D-26-07694R2 Dear Dr. Boyom, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Seth Agyei Domfeh, PhD Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer’s Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: All the comments have been addressed, the manuscript is clear and easily understood and has been improved significantly. The manuscript can be accepted for publication. Reviewer #2: 1. This suggestion is not carried out properly and it should be rectified (Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears first time in the abstract and the remaining for the text and then use only the abbreviation). For example, in line numbers 75 and 76 both form is given for interleukin-1beta (IL-1β), interleukin-6 (IL-6) and the same is repeated in line number 230 and it should be replaced as IL-1β, IL-6, respctively, and these types of corrections need to be checked all other abbreviations used in the manuscript. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Dr. A. Vijaya Anand ********** PONE-D-26-07694R2 PLOS One Dear Dr. Boyom, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Seth Agyei Domfeh Academic Editor PLOS One